Table 1.
Summary of Active Clinical Trials in Brain and Solid Tumors Using Oncolytic Virus Therapy
| Trial Title | Phase | Intervention | Location(s) | NCT Number |
|---|---|---|---|---|
| Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma Newly Diagnosed in Pediatric Patients | I | DNX-2401, an adenovirus that replicates in cells with abnormal Rb pathway | Clinica Universidad de Navarra, Navarra, Spain | NCT03178032 |
| Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients | I/IIa | combination of TG6002 and 5-flucytosine | Groupe Hospitalier Pitié-Salpêtrière, Paris, France | NCT03294486 |
| Neural Stem Cell Oncolytic Adenoviral Virotherapy of Newly Diagnosed Malignant Glioma | I | neural stem cells loaded with oncolytic adenovirus | Northwestern Memorial Hospital, Chicago, IL, USA | NCT03072134 |
| A Randomized Phase 2 Study of Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) Alone or in Combination With Lomustine in Recurrent WHO Grade IV Malignant Glioma Patients | II | oncolytic polio and rhinovirus recombinant (PVSRIPO) with or without lomustine | Preston Robert Tisch Brain Tumor Center at Duke University, Durham, NC, USA | NCT02986178 |
| Phase Ib Study of Oncolytic Polio/Rhinovirus Recombinant Against Recurrent Malignant Glioma in Children | Ib | polio and rhinovirus recombinant (PVSRIPO) | Duke University Medical Center, Durham, NC, USA | NCT03043391 |
| Phase I Clinical Trial of HSV G207 Alone or With a Single Radiation Dose in Children With Recurrent Supratentorial Brain Tumors | I | G207, an oncolytic herpes simplex virus-1 | Children’s of Alabama, Birmingham, AL, USA | NCT02457845 |
| A Phase 1b, Randomized, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) and Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma (TARGET-I) | Ib | intratumoral injection of DNX-2401, interferon-gamma | Moffitt Cancer Center, Tampa, FL, USA; The Ohio State University, Columbus, OH, USA; Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA; University of Texas MD Anderson Cancer Center, Houston, TX, USA | NCT02197169 |
| A Phase 1 Study of M032 (NSC 733972), a Genetically Engineered HSV-1 Expressing IL-12, in Patients With Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma | I | M032, an oncolytic herpes simplex virus that secretes IL-12 | University of Alabama at Birmingham, Birmingham, AL, USA | NCT02062827 |
| A Phase I Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2, a Genetically Engineered HSV-1 Virus, and Immunomodulation With Cyclophosphamide | I | rQNestin34.5v.2, a viral vector made from HSV | Dana-Farber/Brigham and Women’s Cancer Center, Boston, MA, USA | |
| Trial of C134 in Patients With Recurrent GBM (C134-HSV-1) | I | C134, a chimeric HCMV/HSV virus | University of Alabama at Birmingham, Birmingham, AL, USA | NCT03657576 |
| Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane in Patients With Advanced Solid Tumors | I | VCN-01, an oncolytic adenovirus, with or without gemcitabine and abraxane | Hospital Vall d’Hebron, Institut Català d’Oncologia, Barcelona, Spain | NCT02045602 |
| Immunization Strategy with Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic/Advanced Solid Tumors (ISI-JX) | I | Pexa-Vec, a recombinant vaccinia virus with GM-GCF and ipilimumab | Centre Léon Bérard. Lyon, France | NCT02977156 |